https://www.macrotrends.net/stocks/charts/ZLDPF/zealand-pharma/total-liabilities
Zealand Pharma Total Liabilities 2017-2025 | ZLDPF | MacroTrends
Zealand Pharma total liabilities from 2017 to 2025. Total liabilities can be defined as the total value of all possible claims against the corporation.
zealand pharmatotal liabilities20172025macrotrends
https://www.barchart.com/stocks/quotes/ZEAL.C.DX/overview
ZEAL.C.DX - Zealand Pharma A/S Stock Price - Barchart.com
Zealand Pharma A/S stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions.
zealand pharmas stockdx
https://menafn.com/1111058934/The-Zealand-Pharma-Board-Of-Directors-Proposes-To-Elect-Camilla-Sylvest-To-The-Board-Of-Directors-At-An-Upcoming-Extraordinary-General-Meeting
The Zealand Pharma Board Of Directors Proposes To Elect Camilla Sylvest To The Board Of Directors...
The Zealand Pharma Board Of Directors Proposes To Elect Camilla Sylvest To The Board Of Directors At An Upcoming Extraordinary General Meeting. Press release -...
board of directorszealand pharma
https://www.macrotrends.net/stocks/charts/ZLDPF/zealand-pharma/quick-ratio
Zealand Pharma Quick Ratio 2017-2025 | ZLDPF | MacroTrends
Historical quick ratio values for Zealand Pharma (ZLDPF) over the last 10 years.
zealand pharmaquick ratio20172025macrotrends
https://www.compuserve.com/pf/story/0022/20260507/1001180409.htm
Zealand Pharma Announces Financial Results for the First Three Months of 2026
first three monthszealand pharmafinancial resultsfor the
https://www.devdiscourse.com/article/headlines/3899491-zealand-pharmas-obesity-drug-boosts-q1-outlook
Zealand Pharma's Obesity Drug Boosts Q1 Outlook | Headlines
Danish drug developer Zealand Pharma reported a smaller-than-expected first-quarter operating loss. The company's strong results were driven by momentum in its...
zealand pharmaobesity drugboostsq1outlook
https://www.wallstreet-online.de/aktien/zealand-pharma-aktie/historische-kurse
Historische Kurse zu Zealand Pharma | A0YJW7 | wallstreetONLINE
Historische Kurse zu Zealand Pharma tagesgenau abrufbar. Rendite und Renditeverteilungen zu A0YJW7
zealand pharmahistorischekursezuwallstreetonline
https://www.globalbankingandfinance.com/zealand-pharma-posts-smaller-than-expected-q1-loss-obesity/
Zealand Pharma Reports Smaller Q1 Loss, Boosted by Obesity Drugs
May 7, 2026 - Zealand Pharma posts a smaller-than-expected Q1 loss and announces $200 million buyback as obesity drug pipeline drives optimism.
zealand pharmareportssmallerq1loss
https://www.biospace.com/zealand-pharma-to-participate-in-upcoming-healthcare-investor-conferences-in-june-2024
Zealand Pharma to participate in upcoming healthcare investor conferences in June 2024 - BioSpace
May 29, 2024 - Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines,...
zealand pharmato participate
https://www.devdiscourse.com/article/headlines/3899503-zealand-pharma-surprises-with-smaller-loss-and-bold-200m-share-buyback
Zealand Pharma Surprises with Smaller Loss and Bold $200M Share Buyback | Headlines
Zealand Pharma exceeded market expectations in Q1 with a reduced operating loss, citing robust obesity drug pipeline progress. The company announced a $200...
zealand pharma
https://www.ey.com/en_nz/insights/life-sciences/what-pharma-supply-chain-transformation-means-for-tax
What pharma supply chain transformation means for tax | EY - New Zealand
Businesses looking to create visibility and resilience in their supply chains must loop in tax and transfer pricing teams early in the process. Learn more.
supply chain transformationpharma
https://www.biospace.com/zealand-pharma-to-participate-in-morgan-stanley-20th-annual-global-healthcare-conference
Zealand Pharma to Participate in Morgan Stanley 20th Annual Global Healthcare Conference - BioSpace
Sep 7, 2022 - Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078,) a biotechnology company focused on the discovery and development of innovative peptide-based...
https://www.biospace.com/boehringer-ingelheim-and-zealand-pharma-announce-phase-ii-trial-showed-14-9-percent-weight-loss-in-people-living-with-obesity-or-overweight
Boehringer Ingelheim and Zealand Pharma announce phase II trial showed 14.9% weight loss in people...
May 10, 2023 - Boehringer Ingelheim and Zealand Pharma A/S announced that patients treated with BI 456906 achieved up to 14.9% weight loss after 46 weeks, using the planned...
https://www.marketscreener.com/news/zealand-pharma-a-s-announces-the-appointment-of-eric-rojas-as-head-of-investor-relations-effective-ce7e50dddf8bf525
Zealand Pharma A/S Announces the Appointment of Eric Rojas as Head of Investor Relations, Effective...
Apr 14, 2026 - Zealand Pharma A/S announced the appointment of Eric Rojas as Vice President and Head of Investor Relations, effective April 15, 2026. Eric will report to...
https://www.roche.com/media/releases/med-cor-2025-03-12
Roche enters into an exclusive collaboration & licensing agreement with Zealand Pharma to...
Agreement allows for a range of potentially best-in-class therapy options as monotherapy and fixed dose combination with Roche`s lead incretin asset CT...